Half Year Results 

EKF earnings beat bosses’ expectations

EKF earnings beat bosses’ expectations

EKF Diagnostics’ (EKF) top line was dampened by two factors during the half year to June. First, foreign exchange movements; at constant currencies, revenues would have remained broadly flat. Second, the completion of the group’s Saudi tender in the second half of 2017, which contributed £1.1m in sales to last year’s half-year results, specifically benefiting the diabetes business. This time, the respective division’s sales dropped by a quarter to £4.4m. It's all about timing but, reassuringly, EKF has boosted its diabetes offering in the US via an exclusive distribution contract with Asahi Kasei Pharma Corp.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now